|
1
|
Zuckerkandl E: About sympathetic
paraganglions in the retroperitoneal space of man. Verh Anat Ges.
15:95–107. 1901.(In German).
|
|
2
|
Unsicker K, Huber K, Schütz G and Kalcheim
C: The chromaffin cell and its development. Neurochem Res.
30:921–925. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kohn A: The paraganglia. Arch Mikrosk
Anat. 52:262–265. 1903.(In German).
|
|
4
|
Schober A, Parlato R, Huber K, Kinscherf
R, Hartleben B, Huber TB, Schütz G and Unsicker K: Cell loss and
autophagy in the extra-adrenal chromaffin organ of Zuckerkandl are
regulated by glucocorticoid signalling. J Neuroendocrinol.
25:34–47. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
West GB, Shepherd DM, Hunter RB and
McGregor AR: The function of the organs of Zuckerkandl. Clin Sci.
12:317–325. 1953.PubMed/NCBI
|
|
6
|
Martucci VL and Pacak K: Pheochromocytoma
and paraganglioma: Diagnosis, genetics, management, and treatment.
Curr Probl Cancer. 38:7–41. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lodish MB, Adams KT, Huynh TT, Prodanov T,
Ling A, Chen C, Shusterman S, Jimenez C, Merino M, Hughes M, et al:
Succinate dehydrogenase gene mutations are strongly associated with
paraganglioma of the organ of Zuckerkandl. Endocr Relat Cancer.
17:581–588. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Subramanian A and Maker VK: Organs of
Zuckerkandl: Their surgical significance and a review of a century
of literature. Am J Surg. 192:224–234. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ayala-Ramirez M, Feng L, Johnson MM, Ejaz
S, Habra MA, Rich T, Busaidy N, Cote GJ, Perrier N, Phan A, et al:
Clinical risk factors for malignancy and overall survival in
patients with pheochromocytomas and sympathetic paragangliomas:
Primary tumor size and primary tumor location as prognostic
indicators. J Clin Endocrinol Metab. 96:717–725. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhuang Z, Yang C, Lorenzo F, Merino M,
Fojo T, Kebebew E, Popovic V, Stratakis CA, Prchal JT and Pacak K:
Somatic HIF2A gain-of-function mutations in paraganglioma with
polycythemia. N Engl J Med. 367:922–930. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Imperiale A, Moussallieh FM, Sebag F,
Brunaud L, Barlier A, Elbayed K, Bachellier P, Goichot B, Pacak K,
Namer IJ and Taïeb D: A new specific succinate-glutamate
metabolomic hallmark in SDHx-related paragangliomas. PLoS One.
8:e805392013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Percy MJ, Furlow PW, Lucas GS, Li X,
Lappin TR, McMullin MF and Lee FS: A gain-of-function mutation in
the HIF2A gene in familial erythrocytosis. N Engl J Med.
358:162–168. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Taïeb D, Yang C, Delenne B, Zhuang Z,
Barlier A, Sebag F and Pacak K: First report of bilateral
pheochromocytoma in the clinical spectrum of HIF2A-related
polycythemia-paraganglioma syndrome. J Clin Endocrinol Metab.
98:E908–E913. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang C, Sun MG, Matro J, Huynh TT,
Rahimpour S, Prchal JT, Lechan R, Lonser R, Pacak K and Zhuang Z:
Novel HIF2A mutations disrupt oxygen sensing, leading to
polycythemia, paragangliomas, and somatostatinomas. Blood.
121:2563–2566. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pacak K, Chew EY, Pappo AS, Yang C,
Lorenzo FR, Wilson MW, Aronow MB, Young JA, Popovic V and Zhuang Z:
Ocular manifestations of hypoxia-inducible factor-2α
paraganglioma-somatostatinoma-polycythemia syndrome. Ophthalmology.
121:2291–2293. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pacak K, Jochmanova I, Prodanov T, Yang C,
Merino MJ, Fojo T, Prchal JT, Tischler AS, Lechan RM and Zhuang Z:
New syndrome of paraganglioma and somatostatinoma associated with
polycythemia. J Clin Oncol. 31:1690–1698. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Welander J, Andreasson A, Brauckhoff M,
Bäckdahl M, Larsson C, Gimm O and Söderkvist P: Frequent
EPAS1/HIF2α exons 9 and 12 mutations in non-familial
pheochromocytoma. Endocr Relat Cancer. 21:495–504. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Comino-Méndez I, de Cubas AA, Bernal C,
Álvarez-Escolá C, Sánchez-Malo C, Ramírez-Tortosa CL, Pedrinaci S,
Rapizzi E, Ercolino T, Bernini G, et al: Tumoral EPAS1 (HIF2A)
mutations explain sporadic pheochromocytoma and paraganglioma in
the absence of erythrocytosis. Hum Mol Genet. 22:2169–2176. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Favier J, Buffet A and Gimenez-Roqueplo
AP: HIF2A mutations in paraganglioma with polycythemia. N Engl J
Med. 367:2161–2162. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Keith B, Johnson RS and Simon MC: HIF1α
and HIF2α: Sibling rivalry in hypoxic tumour growth and
progression. Nat Rev Cancer. 12:9–22. 2011.PubMed/NCBI
|
